1. Home
  2. MPLT vs AFYA Comparison

MPLT vs AFYA Comparison

Compare MPLT & AFYA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo MapLight Therapeutics Inc.

MPLT

MapLight Therapeutics Inc.

HOLD

Current Price

$36.90

Market Cap

1.3B

Sector

Health Care

ML Signal

HOLD

Logo Afya Limited

AFYA

Afya Limited

HOLD

Current Price

$13.92

Market Cap

1.3B

Sector

Real Estate

ML Signal

HOLD

Company Overview

Basic Information
Metric
MPLT
AFYA
Founded
2018
1999
Country
United States
Brazil
Employees
133
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Other Consumer Services
Sector
Health Care
Real Estate
Exchange
Nasdaq
Nasdaq
Market Cap
1.3B
1.3B
IPO Year
N/A
2019

Fundamental Metrics

Financial Performance
Metric
MPLT
AFYA
Price
$36.90
$13.92
Analyst Decision
Strong Buy
Hold
Analyst Count
7
5
Target Price
$32.67
$17.00
AVG Volume (30 Days)
563.2K
107.4K
Earning Date
05-28-2026
05-08-2026
Dividend Yield
N/A
4.90%
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$10.43
Revenue Next Year
N/A
$7.15
P/E Ratio
N/A
$9.30
Revenue Growth
N/A
N/A
52 Week Low
$12.24
$13.00
52 Week High
$40.43
$16.47

Technical Indicators

Market Signals
Indicator
MPLT
AFYA
Relative Strength Index (RSI) 54.74 41.35
Support Level $26.20 $13.48
Resistance Level $40.43 $15.54
Average True Range (ATR) 2.75 0.47
MACD -0.46 -0.07
Stochastic Oscillator 35.78 16.71

Price Performance

Historical Comparison
MPLT
AFYA

About MPLT MapLight Therapeutics Inc.

MapLight Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing treatments for central nervous system disorders. Its discovery platform identifies neural circuits causally linked to disease and targets them for therapeutic modulation, aiming to improve efficacy, safety, tolerability, and ease of use. The company was founded by leaders in psychiatry and neuroscience research to address the lack of circuit-specific pharmacotherapies. Its product candidate, ML-007C-MA, is a fixed-dose combination of an M1/M4 muscarinic agonist and a peripherally acting anticholinergic, being developed for schizophrenia and Alzheimer's disease psychosis, designed to activate central receptors while mitigating peripheral side effects.

About AFYA Afya Limited

Afya Ltd is a medical education group based in Brazil. Its education portfolio has several courses in addition to Medicine, such as Management, Dentistry, Law, Engineering, Nursing, Psychology, and Accounting Sciences, among others. It has three segments; Undergraduate, deriving key revenue provides educational services through undergraduate courses related to medical school, undergraduate health science and other ex-health undergraduate programs, Continuing Education provides medical education, specialization and graduate courses in medicine, delivered through digital and in-person content; and Medical practice solution provides clinical decision, clinical management and doctor-patient relationships for physicians and provide access, demand and efficiency for the healthcare players.

Share on Social Networks: